Under the accelerated review, the Food and Drug Administration will
make a decision within six months on Roche's application for
Tecentriq's use in patients with metastatic urothelial carcinoma who
are ineligible for cisplatin chemotherapy and who are either
previously untreated or have disease progression at least 12 months
after receiving chemotherapy before or after surgery.
Tecentriq was approved last year for another group of patients with
locally advanced or metastatic urothelial carcinoma as well as
non-small cell lung cancer, the most-common form of lung cancer.
(Reporting by John Miller, editing by John Revill)
[© 2017 Thomson Reuters. All rights
Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.